EFFECTIVENESS OF PRUCALOPRIDE EITHER AS MONOTHERAPY AND COMBINATION THERAPY AND THE QUALITY OF LIFE IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION
Athira Ullas*, Swathy Suresh and Lijo Joseph Thomas
ABSTRACT
Prucalopride is a 5 HT -4 receptor agonist used for the treatment of Chronic Idiopathic Constipation (CIC) where laxatives fail to show its effectiveness. CIC is a common condition defined by infrequent stools, difficulty in passing stools without any underlying cause and it was diagnosed based on Rome IV criteria. The clinical efficacy of Prucalopride was found to be > 3 SCBMs (Spontaneous complete bowel movements) / week over 4 week treatment. The most common treatment associated side effects are head ache, nausea, vomiting, abdominal pain and cramps. The neurological side effect of the drug includes suicidal ideation, visual hallucination and in some cases loss of memory is also reported. The quality of life in patients with CIC is evaluated based on PAC –QOL (Patient assessment of constipation – Quality of life) Questionnaire. This study aims to determine the QoL, and to analyse the effectiveness of Prucalopride either as monotherapy or combination therapy. This is an Observational Cohort study done for a period of 6 months involving 100 patients. From this study among 100 patients, 59 % of the total population has their SCBM increased more than 3 per week over 4 week treatment and 71% of the total population are extremely satisfied after the treatment. From our study effect of Prucalopride as Monotherapy is effective than combination therapy.
Keywords: Chronic Idiopathic Constipation(CIC), Spontaneous Complete Bowel Movement (SCBM), Quality Of Life (QoL), Monotherapy, Combination therapy.
[Full Text Article]
Impact Factor : 6.044
